Author: Ravi Shankar

PRESS RELEASE | October 21st, 2026 – 5.45pm

Q3 2026 REVENUE

SYNERGIE continues its growth momentum in the third quarter of 2026 and reports revenue of €917.2 million, up 11.2% (+2.4% on a like-for-like basis)

in € m	Q3 2026	Q3 2025	Variation	9M 2026	9M 2025	Variation
International	601.2	505.1	+19.0%	1,688.9	1,462.6	15.5%
France	316.0	319.9	-1.2%	938.8	946.0	-0.8%
Total	917.2	825.0	+11.2%	2,627.7	2,408.6	+9.1%

SYNERGIE reported third-quarter 2026 revenue of €917.2 million, up 11.2% compared with the same period in 2025 (+2.4% on a like-for-like basis). For the first nine months of the year, revenue amounted to €2,627.7 million, representing a growth of 9.1% (+2.3% at constant scope and exchange rates). This increase is mainly due to the acquisitions completed in Switzerland and Canada. International operations now account for 64.3% of Group revenue, compared with 60.7% at the end of September 2025.

International revenue increased by +19.0% in the third quarter (+4.6% on a like-for-like basis). This performance includes a scope effect related to acquisitions, representing €70.6 million during the quarter, as well as the solid performance of the Group’s historical operations across several countries.

Southern Europe continued its growth momentum, with revenue increasing by +9.1% in the third quarter, confirming the strength of the Group’s positions in the region. In Northern and Eastern Europe, revenue rose by +11.3% (-1.0% on a like-for-like basis), supported by the integration of the Swiss operations acquired during the year, while on a like-for-like basis activity remained affected by a subdued economic environment. Outside Europe, revenue benefited from the integration of Agilus in Canada.

In France, revenue amounted to €316.0 million in the third quarter, broadly stable compared with the same period in 2025 (-1.2%). In an economic environment that remains complex, the Group’s operations continue to demonstrate resilience.

In an international environment marked by persistent economic and geopolitical uncertainties, SYNERGIE continues its development with both caution and determination. Supported by the resilience of its business model and the diversification of its activities, the Group remains confident in its ability to sustain its growth trajectory.

NEXT EVENT

• Publication of 2026 Revenue on January 27th, 2026, after market closing

Attachment

• Press_Release_CA_Q3_2026_ENG_VDEF

EXHIBIT (a)(5)(A) 

NEWS RELEASE ANNOUNCING TENDER OFFERS 

LUXEMBOURG, Oct. 21, 2026 (GLOBE NEWSWIRE) — BrightFlixx Finance (Luxembourg) S.A., a Luxembourg public limited company (société anonyme) (the “Purchaser”), today announced that it has commenced two concurrent cash tender offers. In the first offer, the Purchaser is offering to purchase all outstanding shares of common stock (the “CVAT Shares”) of Cavitation Technologies, Inc., a Nevada corporation (the “Company”). In the second offer, the Purchaser is offering to purchase all outstanding shares of common stock (the “ABI Shares”) of Alchemy Beverages Inc., a privately held Delaware corporation affiliated with the Company (“Alchemy”).

SHAREHOLDER INFORMATION WEBSITE: https://brightflixx.capital/

CAVITATION TECHNOLOGIES, INC. — THE OFFER

Final Offer Price and Record Date

Under the tender offer for CVAT Shares (the “CVAT Offer”), the final offer price per share (the “Final Offer Price”) will equal (a) a net aggregate purchase price of $35,000,000, less the outstanding liabilities of the Company on the Record Date, divided by (b) the total number of CVAT Shares outstanding on the Record Date. The Record Date for determining the Final Offer Price is December 24, 2026.

Based on recent information reported by the Company, showing outstanding liabilities of approximately $738,000 and 332,820,459 CVAT Shares outstanding as of October 16, 2026, the initial undiluted estimated price would be approximately $0.105 per share. The Final Offer Price will be calculated using the actual number of outstanding CVAT Shares and the Company’s outstanding liabilities existing at the close of the Record Date.

Key Timelines and Extensions

Offer Commencement Date: October 20, 2026.

Record Date: December 24, 2026, which is 45 business days after commencement of the CVAT Offer.

Offer Extension: The initial period of the CVAT Offer consists of 65 business days from and after commencement and is scheduled to expire at 11:59 p.m., Pacific Time or Pacific Daylight Time, as applicable, on January 26, 2027 (the “Expiration Time”). After the Final Offer Price is announced following the Record Date, the Expiration Time will be extended as necessary to provide shareholders at least 30 business days to review the Final Offer Price and decide whether to tender their CVAT Shares.

Key Conditions to the Offer

The CVAT Offer is subject to the satisfaction or waiver of the conditions set forth in the Tender Offer Agreement dated October 9, 2026 between the Purchaser and the Company (the “BF-CVAT Agreement”). The most significant conditions include:

Minimum Tender. A sufficient number of CVAT Shares must be validly tendered to enable the Purchaser to acquire at least 90% of the Company’s outstanding common stock.

Concurrent Alchemy Offer. The conditions to the Purchaser’s concurrent tender offer for Alchemy must be satisfied or waived, and sufficient ABI Shares must be validly tendered to enable the Purchaser to acquire or own at least 90% of Alchemy’s outstanding common stock.

Compliance. The Company must be in compliance with its representations, warranties, and covenants under the BF CVAT Agreement, subject to the materiality standards specified in that agreement.

No Material Adverse Effect. No material adverse effect may have occurred with respect to the Company’s business or financial condition.
Regulatory Approval. The transaction must be reviewed and cleared by the Committee on Foreign Investment in the United States (CFIUS), and no governmental entity may have taken adverse action to block or prevent the acquisition of tendered CVAT Shares.

Delivery of Shares; Payment Services

Shareholders may tender CVAT Shares by delivering physical stock certificates or using book-entry procedures to transfer their shares to Dynamic Stock Transfer, Inc., the designated depositary and paying agent. Dynamic Stock Transfer will receive tendered CVAT Shares, process tender acceptances, and distribute payment for CVAT Shares accepted and purchased by the Purchaser.

ALCHEMY BEVERAGES INC. — THE OFFER

Final Offer Price and Record Date

Under the tender offer for ABI Shares (the “ABI Offer”), the final offer price per share will equal (a) a net aggregate purchase price of $7,000,000, less Alchemy’s outstanding liabilities on the Record Date, divided by (b) the total number of ABI Shares outstanding on the Record Date. The Record Date for determining the final offer price is December 24, 2026.

Based on recent information reported by Alchemy, showing outstanding liabilities of approximately $88,441.81 and 18,798,473 ABI Shares outstanding as of October 16, 2026, the initial undiluted estimated price would be approximately $0.368 per share. The final offer price will be calculated using the actual number of outstanding ABI Shares and Alchemy’s outstanding liabilities existing at the close of the Record Date.

Key Timelines and Extensions

The ABI Offer commenced on October 20, 2026. The Record Date is December 24, 2026. The initial offer period consists of 65 business days after commencement and is scheduled to expire at 11:59 p.m., Pacific Time or Pacific Daylight Time, as applicable, on January 26, 2027. After the Final Offer Price is announced, the Expiration Time will be extended as necessary to provide shareholders at least 30 business days to review the Final Offer Price and decide whether to tender their ABI Shares.

Key Conditions to the ABI Offer

The ABI Offer is subject to the satisfaction or waiver of the conditions set forth in the Tender Offer Agreement dated October 9, 2026 between the Purchaser and Alchemy (the “BF-ABI Agreement”). The most significant conditions include:

Minimum Tender. A sufficient number of ABI Shares must be validly tendered to enable the Purchaser to acquire at least 90% of Alchemy’s outstanding common stock.

Concurrent CVAT Offer. The conditions to the Purchaser’s concurrent tender offer for the Company must be satisfied or waived, and sufficient CVAT Shares must be validly tendered to enable the Purchaser to acquire or own at least 90% of the Company’s outstanding common stock.

Compliance. Alchemy must be in compliance with its representations, warranties, and covenants under the BF-ABI Agreement, subject to the materiality standards specified in that agreement.

No Material Adverse Effect. No material adverse effect may have occurred with respect to Alchemy’s business or financial condition.

Regulatory Approval. The transaction must be reviewed by CFIUS, and no governmental entity may have taken adverse action to block or prevent the acquisition of tendered ABI Shares.

Fairness Opinion

Because Alchemy is privately held and its shares are not listed on a national securities exchange or OTC Markets platform, Alchemy will, pursuant to the BF-ABI Agreement, obtain a fairness opinion from a qualified independent third party regarding the current market value of Alchemy and its capital stock. The fairness opinion may not be used to reduce the final offer price determined following the Record Date, but, depending on the value assigned to Alchemy, may provide a basis for an upward adjustment in the final market price under the ABI Offer and the CVAT Offer.
Delivery and Payment Services

Shareholders may tender ABI Shares by delivering physical stock certificates or using book-entry transfer procedures to transfer their shares to Dynamic Stock Transfer, Inc., the designated depositary and paying agent responsible for processing tender acceptances and distributing payment for ABI Shares accepted and purchased by the Purchaser.

Additional Information and Where to Find It

This press release is for informational purposes only. It is neither an offer to purchase nor a solicitation of an offer to sell shares under either tender offer. The solicitation and offer to buy CVAT Shares are being made only pursuant to the CVAT Offer to Purchase, the CVAT Letter of Transmittal, and related materials filed with the U.S. Securities and Exchange Commission (the “SEC”) on Schedule TO-T. The solicitation and offer to buy ABI Shares are being made
only pursuant to the ABI Offer to Purchase, the ABI Letter of Transmittal, and related materials filed with the SEC in the same Schedule TO-T filing, as amended or supplemented.

Shareholders may review the current public tender-offer materials, SEC filing package, Offer to Purchase documents, Letters of Transmittal, broker and client communications, transaction agreements, and related notices at the BrightFlixx shareholder information website: https://brightflixx.capital/. The website is provided for information only. It does not accept tenders, share certificates, account information, payment instructions, or other tender submissions. Shareholders should follow only the instructions contained in the final tender-offer materials and should consult their own financial, tax, and legal advisers.

Copies of the tender-offer documents may also be obtained free of charge from the SEC’s website, from the Purchaser or the Company, or directly from Dynamic Stock Transfer, Inc., 3347 Cerritos Avenue, Los Alamitos, California 90720, telephone +1 (213) 667-0197.

Forward-Looking Statements

This press release contains forward-looking statements regarding the expected timing, value, and completion of the cash tender offer for CVAT Shares and the concurrent cash tender offer for ABI Shares. Actual results may differ materially because of risks and uncertainties, including whether the conditions to either offer will be satisfied or waived, whether a sufficient number of shares will be tendered to satisfy the 90% minimum condition, whether required regulatory reviews will be completed, and whether the transactions will be consummated in a timely manner or at all. The Purchaser undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

About BrightFlixx Finance (Luxembourg) S.A.

BrightFlixx Finance (Luxembourg) S.A. is a Luxembourg public limited company (société anonyme) qualified as a securitization company under the Luxembourg Securitization Law. BrightFlixx focuses on strategic international investments, corporate asset optimization, and specialized securitization solutions for affiliates and investor portfolios.

Investor and Media Contact

BrightFlixx Finance (Luxembourg) S.A.

Shareholder information website:

https://brightflixx.capital/

CONTACT: office@brightflixxfinance.com

Ivry-sur Seine, October 21, 2026, 5:45 p.m. CET

LFL¹ REVENUE UP +1.8% IN Q3 2026 AND +1.1% IN 9M 2026
GROSS MARGIN RATE INCREASE (+40 bps)
OUTLOOK CONFIRMED

MERGER CONTROL CLEARANCE FROM THE EUROPEAN COMMISSION OBTAINED
TAKEOVER BID TO CLOSE ON NOVEMBER 9, 2026

• 9M 2026 revenue of €6,966 million, up +1.1% LFL¹ compared with 9M 2025²
• 9M online sales up +5.3%, with Click & Collect accounting for close to 50% of online sales
• Gross margin rate up 40 bps compared with 9M 2025²
• 2026 outlook confirmed
• Takeover bid by EP Group:
  • Merger control clearance from the European Commission obtained
  • Offer period closing on November 9, 2026
  • If successful, the Offer should be reopened for at least ten trading days

Enrique Martinez, Chief Executive Officer of Fnac Darty, declared: “Our group is performing very strongly in a complex context, as illustrated by the events of the last few days in France. I would like to thank our teams who have shown exemplary professionalism and commitment in the stores that have been affected by theft and violence. We are determined to quickly restore these stores to be able to welcome our customers again in the best conditions. We are pleased that EP Group’s public takeover bid has obtained the required clearance from the European Commission and can now move forward to completion. Our shareholders have until November 9 to tender their shares.“

KEY FIGURES AT THE END OF SEPTEMBER 2026

	Q3 2026			9M 2026
(€ million)	2025 reported	2025 restated2	2026	2025 reported	2025 restated2	2026
Revenue	2,488.3	2,460.7	2,508.6	6,968.1	6,884.0	6,965.7
Change vs 2025 restated			+1.9%			+1.2%
LFL change1			+1.8%			+1.1%

In Q3 2026, Group revenue amounted to €2,509 million, up +1.8% on a like-for-like basis¹ compared with Q3 2025². France was almost stable at -0.4% LFL¹. The Rest of Europe posted strong growth (+5.0% LFL¹).

At the end of September 2026, revenue was €6,966 million, up +1.1% on a like-for-like basis¹ compared with 9M 2025².

Gross margin rate has increased by 40 bps compared with 9M 2025 restated², primarily due to the growing contribution of services businesses and a favorable product mix.

CHANGES BY DISTRIBUTION CHANNEL

At the end of September 2026, in-store sales were stable. Conversely, online sales increased (+5.3% compared with 9M 2025²) and represented more than 21% of the Group’s total sales, driven in particular by the Group’s marketplaces (direct and reverse). Omnichannel sales (Click & Collect) increased compared with 9M 2025² and represented close to 50% of the Group’s online revenue. These results confirm, once again, the relevance of the omnichannel strategy adopted by Fnac Darty.

CHANGE BY PRODUCT CATEGORY AT THE END OF SEPTEMBER

Domestic appliances posted solid growth, driven by small domestic appliances, particularly floor care, coffee and seasonal products. Large domestic appliances also grew, benefiting from the good performance of air conditioning and refrigeration products in favorable weather conditions.

Consumer electronics recorded slight growth, with contrasting trends across categories. Hardware sales continued to benefit from the end of support for Windows 10 and the ongoing replacement cycle. Telephony sales grew, driven by a good third quarter, while sound, photo and television were slightly down.

Diversification posted mid-single-digit growth, driven in particular by double-digit growth in toys & games.

Services continued to grow, supported by strong momentum in subscription-based offers.

Lastly, editorial products declined, penalized by an unfavorable comparison base in gaming following the successful launch of the Switch 2 in 2025. Books were down in a market with few notable new releases, while audio remained very dynamic thanks to vinyl.

CHANGE BY GEOGRAPHY AT THE END OF SEPTEMBER

France posted a -0.6% decline in LFL¹ revenue compared with 9M 2025². Although weather conditions supported certain categories, activity remained affected by a subdued consumer environment.

Rest of Europe posted an increase in LFL¹ revenue of +3.5% compared with 9M 2025²:

• Italy posted LFL¹ growth of +2.5% across all distribution channels.
• Belgium-Luxembourg recorded LFL¹ growth of +5.2%, driven by strong consumption momentum.
• Portugal posted LFL¹ growth of +8.0%, driven by strong momentum across both brands and all distribution channels. The acquisition of 11 Staples stores will strengthen the brand’s territorial footprint in 2027.
• Spain posted LFL¹ growth of +4.4%, supported by positive momentum across all categories, both in stores and online. Renovated stores performed well.
• Switzerland was down -1.1% LFL¹, mainly impacted by the decline in the book and hardware markets.

UNIEURO

The integration of Unieuro is progressing in line with the announced timetable. The French and Italian teams are working together to deploy the strategic initiatives of the Beyond everyday plan. Operating performance in Italy is satisfactory. The Group confirms its target of at least €20 million in synergies by the end of 2026.

REPAIR & BEYOND

For the ninth consecutive year, Fnac Darty is presenting the results of its after-sales services barometer, which outlines the major durability trends observed in the field. Reported at the beginning of October, it provides objective and independent insight into product reliability and repairability. This new edition notably highlights the solutions available in the event of breakdowns and the expertise of the entire repair sector in dealing with increasingly complex products.

BEYOND DIGITIZED OMNICHANNEL

Opened on October 6, the new Fnac store in Toulouse illustrates the evolution of the brand’s model: smoother customer journeys, enhanced services, modular spaces and personalized support. Designed to adapt to key trading periods and host new events and experiences, it brings together all Fnac product categories, complemented by a Darty corner dedicated to small domestic appliances, a WeFix area for smartphone and tablet repairs, and a Lego shop-in-shop. This new concept reflects the ambitions of Beyond everyday: simplifying the customer experience, strengthening the complementarity between stores, e-commerce, services and repair, and enhancing proximity and expertise.

BEYOND RETAIL

Retailink by Fnac Darty continued to roll out its XXL DOOH offering with a new display at Fnac La Défense, inaugurated this summer, bringing its network of large-format displays in Paris and Nice to six. This expansion is in line with the Group’s strategy to digitize its points of sale and reinforces the ambition of the Group’s retail media agency to offer the most comprehensive premium DOOH Retail Media solution in the French market.

EP GROUP’S TAKEOVER BID FOR FNAC DARTY

Fnac Darty and EP FR HOLDCo, the vehicle controlled by EP Group and established for the purposes of the proposed public tender Offer for the outstanding shares and OCEANEs of Fnac Darty announced on October 20, 2026 that they had received the merger control clearance from the European Commission for the planned acquisition of Fnac Darty.

As a result of the receipt of this decision, which constitutes the last expected approval of the transaction, the French Financial Markets Authority (Autorité des marchés financiers, “AMF”) announced on October 20, 2026 that the Offer for Fnac Darty securities will close on November 9, 2026.

Fnac Darty shareholders and OCEANE holders therefore have until November 9, 2026 to tender their securities to the EP FR HOLDCo Offer.

The Offer price is €35 per share, following the payment on June 5, 2026 of a dividend of €1 per share in respect of the 2025 financial year, and €81.16³ per OCEANE.

The AMF is expected to publish the Offer results notice in the days following November 9, 2026.

The settlement will take place on November 12, 2026.

If successful, the Offer will be reopened for at least ten trading days.

Documentation relating to the Offer is available on Fnac Darty’s website in the section dedicated to the Offer (www.fnacdarty.com/le-groupe/investisseurs/projet-doffre-publique-dachat-de-ep-group/) and on the AMF website (www.amf-france.org).

OUTLOOK

The Group confirms its expectation of an increase in its 2026 current operating margin rate and free cash flow from operations.
Fnac Darty is continuing to implement the strategic roadmap of the Beyond everyday plan, presented on June 11, 2025, and confirms the objectives communicated for 2030.

*********

Q3 2026 REVENUE

Enrique Martinez, Chief Executive Officer and Jean-Brieuc Le Tinier, Group Chief Financial Officer, will host a virtual presentation in French, with simultaneous interpretation into English.

Wednesday, October 21, 2026, at 6:00 p.m. (Central European Time)
5:00 p.m. (UK) – 12:00 p.m. (East Coast USA)

The presentation will be streamed live at this link.

To join the conference call to listen by phone and ask questions:
France: +33 1 70 91 87 04
UK: +44 1 212 818 004
USA: +1 718 705 8796

You can listen to a recording of the presentation at any time, in either French or English, via the website www.fnacdarty.com.

CONTACTS
ANALYSTS/INVESTORS
Domitille Vielle – Head of Investor Relations – domitille.vielle@fnacdarty.com – +33 (0)6 03 86 05 02
Laura Parisot – Investor Relations Manager – laura.parisot@fnacdarty.com – +33 (0)6 64 74 27 18

PRESS
Bénédicte Debusschère – Head of Corporate Communications – benedicte.debusschere@fnacdarty.com – +33 (0)6 48 56 70 71

APPENDIX

The following tables contain individually rounded data. The arithmetical calculations based on rounded data may present some differences with the aggregates or subtotals reported.

REVENUE

in €m	Q3 2025 reported	Q3 2025 restated4	Q3 2026	Change compared with Q3 2025 restated
				Reported	LFL5
France	1,469.4	1,441.9	1,439.6	(0.2)%	(0.4)%
Rest of Europe	1,018.9	1,018.9	1,069.0	+4.9%	+5.0%
o/w Italy	617.0	617.0	643.0	+4.2%	+5.0%
o/w Belgium	159.8	159.8	166.4	+4.1%	+4.1%
o/w Portugal	130.5	130.5	135.7	+4.0%	+6.3%
o/w Spain	63.8	63.8	74.5	+16.8%	+9.6%
o/w Switzerland	47.8	47.8	49.5	+3.6%	+0.3%
Group	2,488.3	2,460.7	2,508.6	+1.9%	+1.8%

in €m	9M 2025 reported		9M 2025 restated1		9M 2026		Change compared with 9M 2025 restated
							Reported		LFL2
France	4,119.9		4,035.8		4,018.5		(0.4)%		(0.6)%
Rest of Europe	2,848.1		2,848.1		2,947.2		+3.5%		+3.5%
o/w Italy	1,737.4		1,737.4		1,777.0		+2.3%		+2.5%
o/w Belgium	439.5		439.5		462.1		+5.1%		+5.2%
o/w Portugal	344.6		344.6		364.1		+5.7%		+8.0%
o/w Spain	192.1		192.1		207.4		+8.0%		+4.4%
o/w Switzerland	134.6		134.6		136.6		+1.5%		(1.1)%
Group	6,968.1		6,884.0		6,965.7		+1.2%		+1.1%

2025 RESTATED1	Q1	Q2	H1	Q3	9M	Q4	H2	FY
in €m
France	1,343.7	1,250.2	2,593.9	1,441.9	4,035.8	2,033.1	3,474.9	6,068.9
Rest of Europe	942.1	887.2	1,829.3	1,018.9	2,848.1	1,412.8	2,431.7	4,260.9
o/w Italy	573.2	547.2	1,120.4	617.0	1737.4	846.4	1,463.3	2,583.7
o/w Belgium	153.0	126.7	279.7	159.8	439.5	191.7	351.5	631.2
o/w Portugal	104.4	109.7	214.1	130.5	344.6	194.4	324.9	539.0
o/w Spain	67.0	61.2	128.3	63.8	192.1	103.5	167.3	295.6
o/w Switzerland	44.4	42.4	86.8	47.8	134.6	76.8	124.6	211.4
Group	2,285.8	2,137.4	4,423.2	2,460.7	6,884.0	3,445.9	5,906.6	10,329.8

STORE NETWORK

	December 31, 2025			September 30, 2026
	Integrated	Franchises	Total	Integrated	Franchises	Total
France1	395	401	796	398	380	778
Rest of Europe	439	249	688	434	241	675
Italy	269	242	511	264	234	498
Belgium	84	–	84	84	–	84
Portugal	45	4	49	46	4	50
Spain	33	3	36	31	3	34
Switzerland	8	–	8	9	–	9
Total Group	834	650	1,484	832	621	1,453

¹ Including 15 stores abroad (3 in Qatar, 6 in Tunisia, 2 in Senegal, 2 in Ivory Coast, 1 in Congo and 1 in Cameroon), 14 stores in the French overseas territories, as well as Nature & Découvertes subsidiaries managed from France.

DEFINITIONS OF ALTERNATIVE PERFORMANCE INDICATORS

Revenue	The Group’s “real” revenue (or income from ordinary activities) corresponds to its reported revenue. The Group uses the notions of change in revenue detailed below.
Current operating income	Fnac Darty uses current operating income as the main management balance. This is defined as the difference between the total operating income and the “Other non-current operating income and expense.” Current operating income is an intermediate line item intended to facilitate the understanding of the entity’s operating performance that can be used as a way to estimate recurring performance. This indicator is presented in a manner that is consistent and stable over the long term in order to ensure the continuity and relevance of financial information.
Change in revenue at a constant exchange rate	Change in revenue at a constant exchange rate means that the impact of changes in exchange rates has been excluded. The exchange rate impact is eliminated by recalculating sales for period N-1 using the exchange rates used for period N.
Change in revenue on a like-for-like basis	Change in revenue on a like-for-like basis means that the impact of changes in the scope of consolidation is corrected so as to exclude the modifications (acquisition, disposal of subsidiary). Revenue of subsidiaries acquired or sold since January 1 of period N-1 are, therefore, excluded when calculating the change (in the event of a significant variation at Group level).
Change in revenue on a same-store basis	The change in revenue on a same-store basis means that the impact of directly owned store openings and closures is excluded. Revenue of stores opened or closed since January 1 of period N-1 is excluded from calculations of the change.

---

1 Like-for-like basis – LFL: excludes currency effects, changes in scope, store openings and closures.
2 Restated data: include the IFRS 5 reclassification of Nature & Découvertes as shown in the IFRS 2025 consolidated financial statements.

3 Calculated on the basis of an interest accrual period from 23 March 2026 to 12 November 2026, being the settlement date of the initial acceptance period of the Offer.
4 Restated data: include the IFRS 5 reclassification of Nature & Découvertes as shown in the IFRS 2025 consolidated financial statements.
5 Like-for-like basis – LFL: excludes the effect of changes in foreign exchange rates, changes in scope, and store openings and closures.

Attachment

• 20261021_Fnac_Darty_PR_Q32026_mel

SASKATOON, Saskatchewan, Oct. 21, 2026 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX), a Canadian pharmacy acquisition and ownership platform, announced today that senior management will present at the Planet MicroCap Toronto 2026 Conference (the “Conference”) at the Arcadian Loft in Toronto on Wednesday, October 28, 2026, at 5:30 P.M. Eastern Time.

Management will also be available to host in-person meetings with registered attendees during the Conference on October 28th and October 29th.

Interested parties can view the live and archived webcast of PharmaCorp’s presentation via the following webcast link:

https://event.summitcast.com/view/iiVo9HYfz9sL9CC5m4Dgpv/QPMMexbgA5BhuGZtkJGs6p

About PharmaCorp Rx Inc.

PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners. Through a combination of capital, strategic support and operational expertise, PharmaCorp is building a national network of community pharmacies under the PharmaChoice Canada banner.

As of the date of this news release, PharmaCorp operates 17 PharmaChoice Canada-bannered pharmacies and intends to continue acquiring both PharmaChoice Canada-bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform in accordance with its strategic alliance with PharmaChoice Canada, where applicable. PharmaCorp shares trade on the TSX Venture Exchange under the symbol PCRX.

PharmaCorp welcomes discussions with pharmacy owners considering succession or sale. For more information about PharmaCorp’s acquisition program and process, please visit www.PharmaCorpRx.ca or contact our team confidentially. PharmaCorp is committed to seamless transitions that protect pharmacy owners’ legacies and continue serving their communities.

For further information, please contact:

Investor Relations
LodeRock Advisors Inc.
Adam Peeler
adam.peeler@pharmacorprx.ca
Tel: (416) 427-1235

Alan Simpson, Executive Chair
Tel: (306) 536-3771

Neither the TSX Venture Exchange nor its Regulation Services Provider, as that term is defined in the policies of the TSX Venture Exchange, accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This news release contains “forward-looking information” regarding the Corporation within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information.

In particular, this news release contains forward-looking information relating to: the Corporation’s participation in the Conference, including the date and time of its presentation and the availability of management for in-person meetings; the availability of a live and archived webcast of the presentation; the Corporation’s focus on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners; the Corporation’s strategy of building a national network of community pharmacies under the PharmaChoice Canada banner through a combination of capital, strategic support and operational expertise; and the Corporation’s intention to continue acquiring PharmaChoice Canada-bannered and independent pharmacies across Canada and to rebrand non-bannered locations under the PharmaChoice Canada platform, where applicable.

This forward-looking information reflects current beliefs and is based on information currently available to the management of the Corporation and on assumptions the Corporation believes are reasonable. These assumptions include, but are not limited to: the Conference proceeding as scheduled; the availability of management to present and attend meetings at the Conference; the ongoing interest from independent pharmacy owners considering succession options; the continued availability of pharmacies for purchase by the Corporation at prices satisfactory to the Corporation; the availability of financing on acceptable terms; and the volume of acquisition opportunities presented to the Corporation being equal to or greater than historical volumes.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Corporation to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the postponement, rescheduling or cancellation of the Conference or the Corporation’s presentation; technical difficulties affecting the webcast; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delays or failures to receive board of directors, third-party or regulatory approvals; competition; changes in legislation, including pharmacy regulation, affecting the Corporation; the timing and availability of external financing on acceptable terms; conclusions of economic evaluations and appraisals; and a lack of qualified, skilled labour or the loss of key individuals.

A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Corporation’s disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although the Corporation has attempted to identify important risks and factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information, as there can be no assurance that the plans, intentions or expectations upon which it is based will occur.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement and represents the expectations of the Corporation as of the date of this news release. Accordingly, it is subject to change after such date. The Corporation expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

SASKATOON, Saskatchewan, Oct. 21, 2026 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX), a Canadian pharmacy acquisition and ownership platform, announced today that senior management will present at the Planet MicroCap Toronto 2026 Conference (the “Conference”) at the Arcadian Loft in Toronto on Wednesday, October 28, 2026, at 5:30 P.M. Eastern Time.

Management will also be available to host in-person meetings with registered attendees during the Conference on October 28th and October 29th.

Interested parties can view the live and archived webcast of PharmaCorp’s presentation via the following webcast link:

https://event.summitcast.com/view/iiVo9HYfz9sL9CC5m4Dgpv/QPMMexbgA5BhuGZtkJGs6p

About PharmaCorp Rx Inc.

PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners. Through a combination of capital, strategic support and operational expertise, PharmaCorp is building a national network of community pharmacies under the PharmaChoice Canada banner.

As of the date of this news release, PharmaCorp operates 17 PharmaChoice Canada-bannered pharmacies and intends to continue acquiring both PharmaChoice Canada-bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform in accordance with its strategic alliance with PharmaChoice Canada, where applicable. PharmaCorp shares trade on the TSX Venture Exchange under the symbol PCRX.

PharmaCorp welcomes discussions with pharmacy owners considering succession or sale. For more information about PharmaCorp’s acquisition program and process, please visit www.PharmaCorpRx.ca or contact our team confidentially. PharmaCorp is committed to seamless transitions that protect pharmacy owners’ legacies and continue serving their communities.

For further information, please contact:

Investor Relations
LodeRock Advisors Inc.
Adam Peeler
adam.peeler@pharmacorprx.ca
Tel: (416) 427-1235

Alan Simpson, Executive Chair
Tel: (306) 536-3771

Neither the TSX Venture Exchange nor its Regulation Services Provider, as that term is defined in the policies of the TSX Venture Exchange, accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This news release contains “forward-looking information” regarding the Corporation within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information.

In particular, this news release contains forward-looking information relating to: the Corporation’s participation in the Conference, including the date and time of its presentation and the availability of management for in-person meetings; the availability of a live and archived webcast of the presentation; the Corporation’s focus on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners; the Corporation’s strategy of building a national network of community pharmacies under the PharmaChoice Canada banner through a combination of capital, strategic support and operational expertise; and the Corporation’s intention to continue acquiring PharmaChoice Canada-bannered and independent pharmacies across Canada and to rebrand non-bannered locations under the PharmaChoice Canada platform, where applicable.

This forward-looking information reflects current beliefs and is based on information currently available to the management of the Corporation and on assumptions the Corporation believes are reasonable. These assumptions include, but are not limited to: the Conference proceeding as scheduled; the availability of management to present and attend meetings at the Conference; the ongoing interest from independent pharmacy owners considering succession options; the continued availability of pharmacies for purchase by the Corporation at prices satisfactory to the Corporation; the availability of financing on acceptable terms; and the volume of acquisition opportunities presented to the Corporation being equal to or greater than historical volumes.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Corporation to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the postponement, rescheduling or cancellation of the Conference or the Corporation’s presentation; technical difficulties affecting the webcast; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delays or failures to receive board of directors, third-party or regulatory approvals; competition; changes in legislation, including pharmacy regulation, affecting the Corporation; the timing and availability of external financing on acceptable terms; conclusions of economic evaluations and appraisals; and a lack of qualified, skilled labour or the loss of key individuals.

A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Corporation’s disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although the Corporation has attempted to identify important risks and factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information, as there can be no assurance that the plans, intentions or expectations upon which it is based will occur.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement and represents the expectations of the Corporation as of the date of this news release. Accordingly, it is subject to change after such date. The Corporation expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

Series	RIKS 37 0115	RIKS 50 0915
ISIN	IS0000033793	IS0000037794
Maturity Date	01/15/2037	09/15/2050
Auction Date	10/23/2026	10/23/2026
Settlement Date	10/28/2026	10/28/2026
10% addition	10/27/2026	10/27/2026

On the Auction Date, between 10:30 am and 11:00 am, the Government Debt Management will auction Treasury bonds in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Payments for the Treasury bonds must be received by the Central Bank before 14:00 on the Settlement Date, and the Bonds will be delivered in electronic form on the same day. Article 6 of the General Terms of Auction for Treasury bonds applies for the right to purchase an additional 10%.

Further reference is made to the description of the Treasury bond and the General Terms of Auction for Treasury bonds on the Government Debt Management website.

For additional information please contact Magnús Freyr Hrafnsson, Government Debt Management, at +354 569 9679.

21 October 2026

HARGREAVE HALE AIM VCT PLC
(the “Company”)

Purchase of shares for cancellation

Hargreave Hale AIM VCT plc announces that on 21 October 2026 the Company purchased 999,037 ordinary shares at a price of 29.93 pence per share for cancellation.

Following the purchase and cancellation of the above shares, 373,146,523 ordinary shares of one pence each will remain in issue, carrying one vote each.  

The Company does not hold any ordinary shares in Treasury. Therefore, the total voting rights in the Company will be 373,146,523.

This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure and Transparency Rules.

END

For further information, please contact:

Canaccord Genuity Asset Management Limited Abbe Martineau

aimvct@canaccord.com +44 20 7523 4525

LEI: 213800LRYA19A69SIT31

In accordance with the press release dated 20 October 2026, the offering of the new Tier 2 Capital Notes was priced and subscribed today with significant demand. Tryg Forsikring A/S has accordingly decided to issue notes for a nominal amount of NOK 400m and SEK 900m (the “Transaction”). The Transaction was more than 2 times oversubscribed at its peak and was placed primarily with Asset Managers and Funds across the Scandinavian countries.

The Transaction will be settled on 30 October 2026. The NOK Notes will have a variable interest rate of 3M NIBOR +115bps per annum and the SEK Notes will have a variable interest rate of 3M STIBOR +115bps per annum. All of the Notes will feature an interest rate step-up of 1.00% per annum from 30 October 2036.

The first interest payment date on the Transaction will be 30 January 2027. The Transaction has scheduled maturity on 30 October 2056, but Tryg Forsikring A/S has the option to prepay the Notes at par on any day from (and including) 30 October 2031 to (and including) 30 January 2032, or on any Interest Payment Date thereafter.

The notes are expected to be listed on Nasdaq Copenhagen.
In connection with the Transaction, Tryg Forsikring A/S will purchase SEK 153m of its outstanding SEK 1,300,000,000 Floating Rate Tier 2 Capital Notes with ISIN DK0030488101 at a price of 100.042%. The purchase is conditional upon certain conditions, including the settlement of the Transaction.

Additional information:
For further information, visit tryg.com tryg.com or contact:

Head of Financial Reporting, Gianandrea Roberti at +45 20 18 82 67 or gianandrea.roberti@tryg.dk
Head of Investor Relations, Robin H. Løfgren at +45 41 86 25 88 or robin.loefgren@tryg.dk

This announcement is for information purposes only and is not intended to, and does not, constitute or form part of any offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities, or the solicitation of any vote or approval in any jurisdiction pursuant to the Transaction or otherwise in any jurisdiction in which such offer, invitation or solicitation is unlawful.

This announcement does not constitute a prospectus, prospectus equivalent document or an exempted document.

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933 (the “US Securities Act”), as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

About Tryg
Tryg is one of the largest insurance companies in the Nordic region with activities in Denmark, Norway and Sweden. Tryg provides peace of mind and value for more than 6 million customers on a daily basis. Tryg A/S is listed on NASDAQ Copenhagen and approximately 49% of the shares are held by TryghedsGruppen smba. TryghedsGruppen, annually, contributes around DKK 700m to peace of mind purposes via TrygFonden.

Notice to U.S. investors
This announcement does not constitute an offer to sell, or a solicitation of offers to purchase or subscribe for, securities in the United States. The securities referred to herein have not been, and will not be, registered under the US Securities Act, and may not be offered, exercised or sold in the United States absent registration or an applicable exemption from registration requirements.

Cautionary note about forward-looking statements
This announcement (including any information incorporated by reference in this announcement), oral statements made regarding the Transaction, and other information published by Tryg Forsikring A/S contain statements which are, or may be deemed to be, “forward-looking statements”. Forward looking statements are prospective in nature and are not based on historical facts, but rather on current expectations and projections of the management of Tryg Forsikring A/S about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements.

Forward looking statements often use words such as “believe”, “expect”, “estimate”, “intend”, “anticipate” and words of a similar meaning, and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved (or, in each case, their negative or other variations). You should not place undue reliance on these forward looking statements, which reflect the current views of Tryg Forsikring A/S, are subject to risks and uncertainties about Tryg Forsikring A/S and are dependent on many factors, some of which are outside of Tryg Forsikring A/S’ control. There are important factors, risks and uncertainties that could cause actual outcomes and results to be materially different. Except as required by law, Tryg Forsikring A/S undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Attachment

• Tryg Forsikring AS Prices Tier 2 Notes

Class A Ordinary Shares Expected to Begin Trading on a Split-Adjusted Basis on October 23, 2026

HONG KONG, Oct. 21, 2026 (GLOBE NEWSWIRE) — Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (“Ping An Bio” or the “Company”) announced that its board of directors has approved a 1-for-40 reverse stock split of the Company’s class A ordinary shares and class B ordinary shares.

The Company’s class A ordinary shares are expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on October 23, 2026. The shares will continue to trade under the ticker symbol “PASW.”

At the extraordinary general meeting (the “EGM”) of shareholders of the Company held on 18 March 2026, at 9:00 a.m., Hong Kong Time, the following matters, among others, were approved and authorized that with effect on a date within one (1) calendar year after the conclusion of the EGM to be determined by the board of directors of the Company (the “Board”): (A) every one thousand (1,000) then issued and unissued class A ordinary shares, or such lesser whole share amount of not being less than two (2) as the Board may determine in its sole discretion, be consolidated into one (1) class A ordinary share (the “Consolidated Class A Share(s)”), (B) every one thousand (1,000) then issued and unissued class B ordinary shares, or such lesser whole share amount of not being less than two (2) as the Board may determine in its sole discretion, be consolidated into one (1) class B ordinary share (the “Consolidated Class B Share(s)”); (C) all fractional entitlements to the issued Consolidated Class A Shares and Consolidated Class B Shares resulting from the share consolidation will not be issued to the shareholders of the Company and instead, any fractional shares that would have resulted from the share consolidation will be rounded up to the next whole number; and (D) the Board be authorized and directed to do all such acts and things as it may consider necessary or desirable for the purpose of effectuating the share consolidation, including determining the definitive ratio and the effective date of the share consolidation and any other changes to the Company’s authorized share capital in connection with and as necessary to effect the share consolidation.

On August 6, 2026, the Board approved unanimously a share consolidation at the ratio of forty (40)-for-one (1) (the “Share Consolidation” or the “Reverse Stock Split”), to be effective on October 23, 2026 (the “Effective Date”), pursuant to which, on the Effective Date, each 40 issued and unissued class A ordinary shares will be automatically combined into one class A ordinary share, and each 40 issued and unissued class B ordinary shares will be automatically combined into one class B ordinary share. Following the Share Consolidation, the par value of each class A ordinary share and each class B ordinary share will be changed from $0.0000625 to $0.0025. All fractional shares resulting from the Share Consolidation will not be issued to shareholders; instead, any fractional entitlements will be rounded up to the next whole number.

As of the date hereof, the Company has 112,867,000 class A ordinary shares and 12,250,000 class B ordinary shares issued and outstanding. Following the share consolidation, the Company expects to have approximately 2,821,675 class A ordinary shares and 306,250 class B ordinary shares issued and outstanding, subject to adjustment for the rounding up of fractional shares. The new CUSIP number for the Company’s class A ordinary shares following the reverse stock split will be G5880S139.

In connection with the Share Consolidation, the Company amended and restated its memorandum and articles of association currently in effect to reflect the adjustment of the number of authorized ordinary shares, the number of class A ordinary shares and class B ordinary shares of the Company and the par value. As advised by our Cayman Islands counsel, Appleby, the Share Consolidation and the third amended and restated memorandum and articles of association may need to be approved and ratified by shareholders at a general meeting.

About Ping An Biomedical Co., Ltd

Ping An Biomedical Co., Ltd. is a one-stop SCM service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare and biomedical technology.

CONTACT: For more information, please contact:

Ping An Biomedical Co., Ltd.

Email: corpsec@pingan365.vip

Celestia Investor Relations

Email: investors@celestiair.com

Expansion extends Alignment’s Nevada presence to three counties, home to more than 554,000 Medicare beneficiaries

LAS VEGAS, Oct. 21, 2026 (GLOBE NEWSWIRE) — Alignment Health Plan, an award-winning Medicare Advantage plan from Alignment Health, today announced it will expand into Nye County beginning Jan. 1, 2027, offering new Medicare Advantage plan options to local seniors. With the expansion, Alignment Health Plan will serve Clark, Nye and Washoe counties, which are home to more than 554,000 Medicare beneficiaries, according to the Centers for Medicare & Medicaid Services (CMS) data¹.

With the addition of Nye County, Alignment Health’s 2027 Nevada portfolio features six Medicare Advantage plans across three counties supported by more than 6,500 physicians and access to premier provider partners. People with Medicare living in the service area can choose from a co-branded plan with Intermountain Health, plans with Instacart, a plan that helps reduce their Medicare Part B premium and specialized plans for people living with diabetes or heart conditions.

“Choosing the right Medicare coverage and getting the care you need shouldn’t be a challenge,” said Dawn Maroney, president of Alignment Health and CEO of Alignment Health Plan. “We’re excited to expand into Nye County and serve more Nevada seniors with the kind of care and support that treats them as people, not policies. By connecting members to trusted local providers and personalized guidance, we can help them spend less time navigating the health care system and more time focusing on what matters most: staying healthy, independent and engaged in their communities.”

Building on Trusted Nevada Provider Relationships

Members have access to nearby primary care providers, specialists and hospitals through health systems and medical groups in Clark, Nye and Washoe counties.

• Intermountain Health in Clark and Nye counties. Through Alignment’s relationship with Intermountain Health, members in Clark and Nye counties have access to coordinated care delivered through one of the region’s leading healthcare systems, including senior-focused primary care, specialty care, urgent care and telehealth services.
• Trusted local providers. Clark County members can also see providers from The Valley Health System, University Medical Center, Dignity Health and UNLV Health, and Washoe County members have access to providers from Prime Healthcare and Pinnacle Medical Group, among others.

Proven Quality and Member Experience

For 2027, Alignment’s Nevada HMO contract is rated 4 out of 5 stars, and its HMO contract that includes the Clark County Platinum + Instacart and Smart plans is rated 4.5 out of 5 stars. Medicare evaluates plans annually using a 5-star rating system to help consumers compare quality and performance, with higher ratings reflecting strong performance across measures such as member experience, customer service and care coordination.

More Choice and Support for Nevada Seniors

Alignment Health’s 2027 Medicare Advantage plans are designed to help Nevada seniors find coverage that fits their health needs, budget and lifestyle. Alignment Health + Intermountain Health (HMO), available in Clark and Nye counties, lowers its out-of-pocket maximum for 2027. In Clark County, Alignment Health Platinum + Instacart (HMO) includes a quarterly grocery allowance on Instacart for qualifying members, and Alignment Health Smart (HMO) helps reduce members’ Medicare Part B premium.

Members living with diabetes or heart conditions can choose Heart & Diabetes (HMO C-SNP) in Clark and Washoe counties, with up to $204 monthly Essentials allowance for eligible groceries and everyday health-related expenses².

All members have access to Alignment’s 24/7 concierge team for personalized support, including help understanding their benefits, finding the right doctor, coordinating care and receiving answers when they need them. Depending on the plan, members may also enjoy benefits such as $0 copays on more than 10,000 prescribed medications, over-the-counter and grocery² allowances, fitness programs and in-home support.

Medicare’s Annual Enrollment Period runs Oct. 15 through Dec. 7, 2026, with coverage taking effect Jan. 1, 2027. To learn more about Alignment Health’s 2027 Medicare Advantage plans in Nevada, visit alignmenthealthplan.com or call 1-888-979-2247.³

About Alignment Health

Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.

Media Contact:
Jerry Slowey
publicrelations@ahcusa.com

Y0141_27444EN_M

¹ Centers for Medicare & Medicaid Services Medicare Advantage/Part D Contract and Enrollment Data, September 2026 MA State/County Penetration
² Special supplemental benefits for the chronically ill (SSBCI)-qualifying chronic conditions include congestive heart failure (CHF), dementia, diabetes, and stroke. Other chronic conditions may apply. Medical records will be used to establish the member qualification. The benefits mentioned are a part of a special supplemental program for the chronically ill. Not all members qualify because other eligibility and coverage criteria also apply.
³ Alignment Health Plan is an HMO, HMO POS, HMO C-SNP, HMO D-SNP and PPO plan with a Medicare contract and a contract with the California, Nevada, North Carolina and Texas Medicaid programs. Enrollment in Alignment Health Plan depends on contract renewal. The benefit information provided is a summary, not a complete description of benefits. For more information, contact the plan. Call 1-888-979-2247 (TTY: 711), 8 a.m. to 8 p.m. Monday through Friday, for more information. Other providers are available in our network.